Portada›Lunes 24 de noviembre de 2025
Biomédicas del NASDAQ ante la SEC, lunes 24 de noviembre de 2025
Los 25 documentos que 19 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.
← viernes 21 de noviembre de 2025 · martes 25 de noviembre de 2025 →
Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.
Emisiones y dilución
- BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…United States dollar (or units thereof); and • “£,” “pence” and “p” each refer to the British pound sterling (or units thereof). On March 27, 2023, following shareholder approval at a general meeting, we effected a one-for-20 reverse stock split of our Ordinary Shares, and our consolidated Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM, on a split-adjusted basis as of such date. No fractional…
- BDRXBiodexa Pharmaceuticals Plc424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…United States dollar (or units thereof); and • “£,” “pence” and “p” each refer to the British pound sterling (or units thereof). On March 27, 2023, following shareholder approval at a general meeting, we effected a one-for-20 reverse stock split of our Ordinary Shares, and our consolidated Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM, on a split-adjusted basis as of such date. No fractional…
- ENLVEnlivex Ltd.424B5Nueva emisión de acciones con precioEDGAR
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-286956 Prospectus Supplement (to Prospectus Dated May 12, 2025) Up to $299,553,108 of Ordinary Shares On November 24, 2025, we entered into an At-The-Market Sales Agreement (the “Sales Agreement”), with BTIG, LLC (the “Sales Agent”), relating to the sale of our ordinary shares, par value NIS 0.40 per share (“ordinary shares”) covered by this prospectus supplement. In accordance…
- KPTIKaryopharm Therapeutics Inc.424B3Prospecto suplementario o de reventaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated…
- KPTIKaryopharm Therapeutics Inc.424B3Prospecto suplementario o de reventaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- DRMADermata Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
Participaciones y control
- ALMSALUMIS INC.SC 13DCambio en participación significativaEDGAR
- NKTXNkarta, Inc.SC 13D/ACambio en participación significativaEDGAR
- VRCAVerrica Pharmaceuticals Inc.SC 13DCambio en participación significativaEDGAR
Informes y hechos relevantes
- PMNProMIS Neurosciences Inc.8-KCambio de estatutosEDGAR
En el documentoContrasplit de accionestexto original ▸
…October 3, 2025 (the “Proxy Statement”) in connection with the Special Meeting. The text of the Articles of Amendment was included in Appendix A of the Proxy Statement. On November 17, 2025, the Board approved a reverse stock split of the Common Shares at a ratio of one-for-twenty-five. Effective as of 12:01 a.m. Eastern Time on November 28, 2025, the Company filed the Articles Amendment to effect one-for-twenty-five reverse stock…
En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸
…range of ratios for a reverse stock split authorized by the stockholders of the company at the 2025 Special Meeting of Stockholders of the Company held on November 17, 2025. On January 8, 2025, ProMIS received a deficiency letter from The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, for the last 30 consecutive business days, the closing bid price of the Common Shares had not been maintained at the minimum required…
- SCLXScilex Holding Co8-KVenta de acciones no registrada (colocación privada)EDGAR
- VRCAVerrica Pharmaceuticals Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- BCDABioCardia, Inc.8-KOtros hechos relevantesEDGAR
- CPIXCUMBERLAND PHARMACEUTICALS INC8-KNuevo acuerdo materialEDGAR
- HALOHALOZYME THERAPEUTICS, INC.8-KCambio en el consejo o la direcciónEDGAR
- INABIN8BIO, INC.8-KOtros hechos relevantesEDGAR
- IVVDInvivyd, Inc.8-KOtros hechos relevantesEDGAR
- MRNAModerna, Inc.8-KNuevo acuerdo materialEDGAR
- NBIXNEUROCRINE BIOSCIENCES INC8-KCambio en el consejo o la direcciónEDGAR
- TELOTelomir Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
- TNXPTonix Pharmaceuticals Holding Corp.8-KOtros hechos relevantesEDGAR
Juntas de accionistas
← viernes 21 de noviembre de 2025 · martes 25 de noviembre de 2025 →
Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.